Rep. Dwight Evans Sells Thermo Fisher Scientific Inc. (NYSE:TMO) Stock

Representative Dwight Evans (Democratic-Pennsylvania) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on May 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on May 7th. The trade occurred in the Representative’s “CETERA” account.

Representative Dwight Evans also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of American Tower (NYSE:AMT) on 5/11/2026.
• Sold $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 5/7/2026.
• Sold $1,001 – $15,000 in shares of Quanta Services (NYSE:PWR) on 5/7/2026.
• Sold $15,001 – $50,000 in shares of Micron Technology (NASDAQ:MU) on 3/24/2026.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $6.34 during midday trading on Tuesday, reaching $448.34. 3,418,464 shares of the stock were exchanged, compared to its average volume of 2,338,677. The firm has a market cap of $166.61 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 1.94 and a beta of 0.88. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99. The firm has a 50-day simple moving average of $484.46 and a two-hundred day simple moving average of $541.15. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TMO shares. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $616.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Howard Capital Management Inc. lifted its holdings in Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after purchasing an additional 16 shares in the last quarter. Petros Family Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 3.9% during the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock worth $264,000 after acquiring an additional 17 shares during the period. Salomon & Ludwin LLC raised its holdings in shares of Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock worth $669,000 after acquiring an additional 17 shares during the period. Financial Management Network Inc. raised its holdings in shares of Thermo Fisher Scientific by 3.7% during the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock worth $248,000 after acquiring an additional 18 shares during the period. Finally, Pallas Capital Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock worth $728,000 after acquiring an additional 18 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

About Representative Evans

Dwight Evans (Democratic Party) is a member of the U.S. House, representing Pennsylvania’s 3rd Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027.

Evans (Democratic Party) is running for re-election to the U.S. House to represent Pennsylvania’s 3rd Congressional District. He declared candidacy for the 2026 election.

Evans earned his A.A. from the Community College of Philadelphia in 1973 and his bachelor’s degree from La Salle College in 1975. He then attended Graduate Work at Temple University from 1975 to 1976. His professional experience includes working as an employment counselor/job developer for the Urban League of Philadelphia and as a teacher in the Philadelphia Public School System.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.